Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis (Q43996392)

28 November 2017

Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

28 November 2017

0 references

0 references

7

1 reference

28 November 2017

1

Ying Waeckerle-Men

0 references

Nicolas Bruffaerts

object named as

Nicolas Bruffaerts

2

0 references

Peter Sander

object named as

Peter Sander

5

0 references

Thomas M Kündig

6

object named as

Thomas M Kündig

1 reference

28 November 2017

Ying Waeckerle-Men

1

1 reference

28 November 2017

Yuan Liang

3

1 reference

28 November 2017

Fabienne Jurion

4

1 reference

28 November 2017

Pål Johansen

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

25 December 2012

1 reference

28 November 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

28 November 2017

31

1 reference

28 November 2017

7

1 reference

28 November 2017

1057-1064

1 reference

HIV and Tuberculosis: a Deadly Human Syndemic

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Antigen Load Governs the Differential Priming of CD8 T Cells in Response to the Bacille Calmette Guerin Vaccine or Mycobacterium tuberculosis Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

The immunogenicity of single and combination DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Immunological biomarkers of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Cell-mediated immune responses in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

An antimicrobial activity of cytolytic T cells mediated by granulysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Th1 memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Tuberculosis vaccines: a strategic blueprint for the next decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

New vaccines for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Fact and fiction in tuberculosis vaccine research: 10 years later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Recombinant Mycobacterium bovis BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Mycobacterium tuberculosis prevents inflammasome activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Direct intralymphatic injection of peptide vaccines enhances immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Bacillus Calmette-Guérin vaccination using a microneedle patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Dendritic-cell trafficking to lymph nodes through lymphatic vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

A role for antigen in the maintenance of immunological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Continuous T cell receptor signaling required for synapse maintenance and full effector potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Control of human host immunity to mycobacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Investigation of the role of CD8+ T cells in bovine tuberculosis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

Evidence behind the WHO guidelines: hospital care for children: what is the evidence that BCG vaccination should not be used in HIV-infected children?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.034

10.1016/J.VACCINE.2012.12.034

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference